- Oyster Point Pharma, Inc.

George Eliades

Member of the Compensation Committee

George Eliades

Oyster Point Pharma Announces New Appointment to Board of Directors

Read more about Oyster Point Pharma Announces New Appointment to Board of Directors

Oyster Point Pharma Announces FDA Acceptance for Filing New Drug Application for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease

Read more about Oyster Point Pharma Announces FDA Acceptance for Filing New Drug Application for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease

Oyster Point Pharma to Participate in the 41st Annual Cowen Healthcare Conference

Read more about Oyster Point Pharma to Participate in the 41st Annual Cowen Healthcare Conference

Oyster Point Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

Read more about Oyster Point Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

Oyster Point Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 18, 2021

Read more about Oyster Point Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 18, 2021

Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference

Read more about Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference

Oyster Point Pharma Submits New Drug Application to the U.S. Food and Drug Administration for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease

Read more about Oyster Point Pharma Submits New Drug Application to the U.S. Food and Drug Administration for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease

Oyster Point Pharma Strengthens Executive Leadership Team with the Appointment of Chief Medical and Chief Scientific Officers

Read more about Oyster Point Pharma Strengthens Executive Leadership Team with the Appointment of Chief Medical and Chief Scientific Officers

Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK)

Read more about Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK)

Information Requests

© 2021 Oyster Point Pharma, Inc. Oyster Point^™ and the Oyster Point logo are trademarks of Oyster Point Pharma, Inc.